New-Dental-Health-Warning-for-Some-Buprenorphine-Products
New Dental Health Warning for Some Buprenorphine Products
January 12, 2022
Cibinqo-Approved-to-Treat-Atopic-Dermatitis
Cibinqo Approved to Treat Atopic Dermatitis
January 14, 2022
New-Dental-Health-Warning-for-Some-Buprenorphine-Products
New Dental Health Warning for Some Buprenorphine Products
January 12, 2022
Cibinqo-Approved-to-Treat-Atopic-Dermatitis
Cibinqo Approved to Treat Atopic Dermatitis
January 14, 2022
Ryaltris-Nasal-Spray-Approved-for-Allergic-Rhinitis

January 13, 2022 – RyaltrisTM (olopatadine hydrochloride/mometasone furoate monohydrate) nasal spray has been FDA approved to treat the symptoms of seasonal allergic rhinitis in patients who are at least 12 years old.

  • Ryaltris combines an antihistamine and a corticosteroid. Recommended dosing is two sprays in each nostril twice daily.
  • Launch date and pricing plans are not yet available. Ryaltris is manufactured by Seqirus.